These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2189 related articles for article (PubMed ID: 32839553)
1. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553 [TBL] [Abstract][Full Text] [Related]
2. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445 [TBL] [Abstract][Full Text] [Related]
3. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097 [TBL] [Abstract][Full Text] [Related]
4. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930 [TBL] [Abstract][Full Text] [Related]
5. Manganese salts function as potent adjuvants. Zhang R; Wang C; Guan Y; Wei X; Sha M; Yi M; Jing M; Lv M; Guo W; Xu J; Wan Y; Jia XM; Jiang Z Cell Mol Immunol; 2021 May; 18(5):1222-1234. PubMed ID: 33767434 [TBL] [Abstract][Full Text] [Related]
6. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380 [TBL] [Abstract][Full Text] [Related]
7. Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy. Yang L; Wang Y; Song Y; Li Z; Lei L; Li H; He B; Cao J; Gao H J Control Release; 2024 Jun; 370():354-366. PubMed ID: 38685387 [TBL] [Abstract][Full Text] [Related]
8. NK cells mediate clearance of CD8 Nicolai CJ; Wolf N; Chang IC; Kirn G; Marcus A; Ndubaku CO; McWhirter SM; Raulet DH Sci Immunol; 2020 Mar; 5(45):. PubMed ID: 32198222 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological Activation of cGAS for Cancer Immunotherapy. Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT Front Immunol; 2021; 12():753472. PubMed ID: 34899704 [TBL] [Abstract][Full Text] [Related]
10. Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death. Guo Y; Qian R; Li Z; Lv T; Yang C; Li W; Pan T; Hou X; Wang Z Life Sci; 2024 Jul; 348():122687. PubMed ID: 38718856 [TBL] [Abstract][Full Text] [Related]
12. Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists. Pan X; Zhang W; Guo H; Wang L; Wu H; Ding L; Yang B Biochem Pharmacol; 2023 Jul; 213():115596. PubMed ID: 37201875 [TBL] [Abstract][Full Text] [Related]
13. The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity. Lim J; Rodriguez R; Williams K; Silva J; Gutierrez AG; Tyler P; Baharom F; Sun T; Lin E; Martin S; Kayser BD; Johnston RJ; Mellman I; Delamarre L; West NR; Müller S; Qu Y; Heger K Cancer Immunol Res; 2024 Jun; 12(6):663-672. PubMed ID: 38489753 [TBL] [Abstract][Full Text] [Related]
14. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609 [TBL] [Abstract][Full Text] [Related]
15. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. Li A; Yi M; Qin S; Song Y; Chu Q; Wu K J Hematol Oncol; 2019 Apr; 12(1):35. PubMed ID: 30935414 [TBL] [Abstract][Full Text] [Related]
16. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents. Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033 [TBL] [Abstract][Full Text] [Related]
17. Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8 Turley JL; Ward RW; Huete-Carrasco J; Muñoz-Wolf N; Roche K; Jin L; Bowie A; Andersson M; Lavelle EC Cell Rep Med; 2024 May; 5(5):101560. PubMed ID: 38729159 [TBL] [Abstract][Full Text] [Related]
19. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer. Yan X; Yao C; Fang C; Han M; Gong C; Hu D; Shen W; Wang L; Li S; Zhu S Int J Biol Sci; 2022; 18(2):585-598. PubMed ID: 35002511 [No Abstract] [Full Text] [Related]